Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial

X Mariette, O Hermine, PL Tharaux… - The Lancet …, 2022 - thelancet.com
Background Patients with COVID-19 pneumonia can have increased inflammation and
elevated cytokines, including interleukin (IL)-6, which might be deleterious. Thus, sarilumab …
被引用次数：36 相关文章

Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial.

The Lancet. Rheumatology, 2021 - europepmc.org
Background Patients with COVID-19 pneumonia can have increased inflammation and
elevated cytokines, including interleukin (IL)-6, which might be deleterious. Thus, sarilumab …
[HTML] nih.gov

[HTML][HTML] Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial

CORIMUNO-19 Collaborative group - The Lancet. Rheumatology, 2022 - ncbi.nlm.nih.gov
Background Patients with COVID-19 pneumonia can have increased inflammation and
elevated cytokines, including interleukin (IL)-6, which might be deleterious. Thus, sarilumab …

Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial

CORIMUNO-19 Collaborative … - The Lancet …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Patients with COVID-19 pneumonia can have increased inflammation and
elevated cytokines, including interleukin (IL)-6, which might be deleterious. Thus, sarilumab …

Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial

X Mariette, O Hermine, PL Tharaux, M Resche-Rigon… - 2022 - lilloa.univ-lille.fr
Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1):
An open-label randomised controlled trial Toggle navigation English français Aide | Contact | À …

Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial

X Mariette, O Hermine, PL Tharaux… - The Lancet …, 2022 - Elsevier
Background Patients with COVID-19 pneumonia can have increased inflammation and
elevated cytokines, including interleukin (IL)-6, which might be deleterious. Thus, sarilumab …
[HTML] hal.science

[HTML][HTML] Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial

X Mariette, O Hermine, PL Tharaux… - The Lancet …, 2022 - hal.science
Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1):
An open-label randomised controlled trial - Archive ouverte HAL Accéder directement au …

Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial.

The Lancet. Rheumatology, 2021 - europepmc.org
Background Patients with COVID-19 pneumonia can have increased inflammation and
elevated cytokines, including interleukin (IL)-6, which might be deleterious. Thus, sarilumab …
[HTML] hal.science

[HTML][HTML] Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial

X Mariette, O Hermine, PL Tharaux… - The Lancet …, 2022 - hal.science
Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1):
An open-label randomised controlled trial - Archive ouverte HAL Accéder directement au …